Program
Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360
Its studies are mostly in Stomach Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Mar 25, 20251 company-led study, 1 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Mar 25, 2025 | Mar 25, 2025 | Mar 31, 2027phase 2 · NCT06921928 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2025First study: phase 2 study in Stomach NeoplasmsFirst studyNCT06921928 · 31 enrolled · United States, China, Germany and more
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT06921928
TargetBeta
CLDN18 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06921928Stomach Neoplasms · United States, China, Germany and more | 2 | Active, not recruiting | Mar 31, 2027 | 31 |
How it is read
Names in the registry
- “AZD4360”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.